- Home
- SBGI vs COLL Comparison
SBGI vs COLL Comparison
Compare SBGI & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SBGI
- COLL
- Stock Information
- Founded
- SBGI 1986
- COLL 2002
- Country
- SBGI United States
- COLL United States
- Employees
- SBGI N/A
- COLL N/A
- Industry
- SBGI Broadcasting
- COLL Biotechnology: Pharmaceutical Preparations
- Sector
- SBGI Industrials
- COLL Health Care
- Exchange
- SBGI Nasdaq
- COLL Nasdaq
- Market Cap
- SBGI 997.6M
- COLL 958.8M
- IPO Year
- SBGI 1995
- COLL 2015
- Fundamental
- Price
- SBGI $14.80
- COLL $30.35
- Analyst Decision
- SBGI Buy
- COLL Strong Buy
- Analyst Count
- SBGI 5
- COLL 4
- Target Price
- SBGI $18.50
- COLL $43.75
- AVG Volume (30 Days)
- SBGI 558.0K
- COLL 283.6K
- Earning Date
- SBGI 08-06-2025
- COLL 08-07-2025
- Dividend Yield
- SBGI 6.76%
- COLL N/A
- EPS Growth
- SBGI N/A
- COLL N/A
- EPS
- SBGI 1.97
- COLL 1.25
- Revenue
- SBGI $3,526,000,000.00
- COLL $664,283,000.00
- Revenue This Year
- SBGI N/A
- COLL $20.04
- Revenue Next Year
- SBGI $9.59
- COLL $3.98
- P/E Ratio
- SBGI $7.52
- COLL $24.19
- Revenue Growth
- SBGI 11.62
- COLL 17.17
- 52 Week Low
- SBGI $12.07
- COLL $23.23
- 52 Week High
- SBGI $18.46
- COLL $42.29
- Technical
- Relative Strength Index (RSI)
- SBGI 63.87
- COLL 54.25
- Support Level
- SBGI $13.31
- COLL $29.28
- Resistance Level
- SBGI $14.18
- COLL $30.83
- Average True Range (ATR)
- SBGI 0.52
- COLL 0.75
- MACD
- SBGI 0.20
- COLL -0.00
- Stochastic Oscillator
- SBGI 94.30
- COLL 51.63
About SBGI Sinclair Inc.
Sinclair Inc. is the owner-operator of the second largest portfolio of television stations in the United States, with 185 full power stations in 86 markets. Of the firm's roughly 600 channels, 150 are affiliated with the four national broadcasters—Fox, ABC, CBS, and NBC—with over 80 other channels aligned with The CW (Nexstar) and MyNetworkTV (Fox). Sinclair owns the Tennis Channel and stakes in Marquee Sports Network and YES Network, providing their content to pay-TV distributors.
About COLL Collegium Pharmaceutical Inc.
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.